

No. 07-01-2010


Medicines in the PNDF to be reimbursed only in hospitals with DOH-accredited Antimicrobial Resistance Surveillance Program

PhilHealth Circular No. 26 s-2009 provides for the use of the PNDF Volume 1, 7th edition as the main reference for PhilHealth drug reimbursement.

As listed on page 134 of the latest edition of the PNDF, it is reiterated that the following drugs can only be reimbursed when used in hospitals with DOH-Accredited Antimicrobial Resistance Surveillance Program:

Generic name	Route	Pharmaceutical forms and strengths
cefepime	Inj.:	500 mg, 1 g, 2 g vial (IM/IV) (as hydrochloride)
ertapenem	Inj.:	1 g powder, vial (IM/IV) (as sodium salt)
levofloxacin	Oral: Inj.:	250 mg, 500 mg, & 750 mg tablet 5mg/mL solution for IV infusion, 100mL vial
meropenem	Inj.:	500 mg & 1 g powder, vial (IV) (as trihydrate)
piperacillin+ tazobactam	Inj.	2 g piperacillin + 250 mg tazobactam per vial (as sodium salt) (IV infusion) 4 g piperacillin + 500 mg tazobactam per vial (as sodium salt) (IV infusion)
vancomycin	Inj.	500 mg & 1 g vial (IV) (as hydrochloride)

Please be guided accordingly.



DR. REY B. AQUINO
President and CEO